⦠on the Singapore Exchange (
SGX). Upcoming stories will examine ⦠interest in listing on the
SGX is âcurrently somewhat modestâ ⦠contributes to better valuations.
SGX-listed biopharma players also lack ⦠foreign, in listing on the
SGX. China Medical Systems, a â¦